Early relapses, onset of progression, and late outcome in multiple sclerosis

JAMA Neurology

Volumn 70, Issue 2, 2013, Pages 214-222

  Scalfari, Antonio ^a   Neuhaus, Anneke ^b   Daumer, Martin ^b   DeLuca, Gabriele C ^c   Muraro, Paolo A ^a   Ebers, George C ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Sylvia Lawry Centre for Multiple Sclerosis Research   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; DISABILITY STATUS SCALE SCORE OF 6; DISABILITY STATUS SCALE SCORE OF 8; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE SCLEROSIS; ONSET AGE; PHYSICAL DISABILITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROBABILITY; SCORING SYSTEM;

EID: 84874074752     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.599     Document Type: Article

References (44)

1. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003; 126(pt 4):770-782.
2. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133(pt 7):1900-1913.
3. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010;133(pt 7):1914-1929.
4. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006;129(pt 3):584-594.
5. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(pt 3):606-616.
6. Tremlett H, Zhao Y, Devonshire V; UBC Neurologists. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol. 2009;256(3):374-381.
7. Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F; LORSEP Group. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol. 2008;15(9):916-921.
8. Eriksson M, Andersen O, Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler. 2003;9(3):260-274.
9. Bejaoui K, Rolak LA. What is the risk of permanent disability from a multiple sclerosis relapse? Neurology. 2010;74(11):900-902.
10. Weinshenker BG. Clinical overview of neuromyelitis optica. Rinsho Shinkeigaku. 2009;49(11):894-895.
11. Cohen BA, Khan O, Jeffery DR, et al. Identifying and treating patients with suboptimal responses. Neurology. 2004;63(12)(suppl 6):S33-S40.
12. Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach. Neurology. 2010;75(4):302-309.
13. Sormani MP, Li DK, Bruzzi P, et al. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology. 2011;77(18):1684-1690.
14. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology. 1993;43(4):655-661.
15. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcuta-neously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis [publishsed correction appears in Lancet. 1999;353(9153):678]. Lancet. 1998; 352(9139):1498-1504.
16. Jacobs LD, Cookfair DL, Rudick RA, et al; The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3):285-294.
17. Johnson KP, Brooks BR, Cohen JA, et al; Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995;45(7):1268-1276.
18. European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352(9139): 1491-1497.
19. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999;46(3):296-304.
20. Rice FM, Filippi M, Comi G; Cladribine MRI Study Group. Cladribine and progressive MS: clinical and MRI outcomes of a multicentre controlled trial. Neurology. 2000;54(5):1145-1155.
21. Ebers GC, Traboulsee A, Li D, et al; Investigators of the 16-Year Long-Term Follow-up Study. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010; 81(8):907-912.
22. Kantarci O, Siva A, Eraksoy M, et al; Turkish Multiple Sclerosis Study Group (TUMSSG). Survival and predictors of disability in Turkish MS patients. Neurology. 1998;51(3):765-772.
23. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y; UBC Neurologists. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology. 2009;73(20):1616-1623.
24. DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM. The contribution of demyelination to axonal loss in multiple sclerosis. Brain. 2006;129(pt 6):1507-1516.
25. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247-269.
26. D'Souza M, Kappos L, Czaplinski A. Reconsidering clinical outcomes in multiple sclerosis: relapses, impairment, disability and beyond. J Neurol Sci. 2008; 274(1-2):76-79.
27. Rieckmann P. Clinical trials in multiple sclerosis: current and future requirements: potential pitfalls. J Neurol. 2008;255(suppl 6):66-68.
28. Ebers GC, Daumer M, Scalfari A. Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach: measuring disability in relapsing-remitting MS. Neurology. 2011;76(11):1025-1026.
29. Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology. 2011;77(13):1246-1252.
30. Kurtzke JF. A new scale for evaluating disability in multiple sclerosis. Neurology. 1955;5(8):580-583.
31. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227-231.
32. Lublin FD, Reingold SC; National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46(4):907-911.
33. Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple sclerosis: a geographically based study, 7: progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain. 1999;122(pt 10):1941-1950.
34. Daumer M, Held U, Ickstadt K, Heinz M, Schach S, Ebers G. Reducing the probability of false positive research findings by pre-publication validation: experience with a large multiple sclerosis database. BMC Med Res Methodol. 2008; 8:18. doi:10.1186/1471-2288-8-18.
35. RDCTR: A Language and Enviroment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
36. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(pt 5): 1175-1189.
37. Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci. 2003;206 (2):135-137.
38. Jones JL, Coles AJ. New treatment strategies in multiple sclerosis. Exp Neurol. 2010;225(1):34-39.
39. Alkawajah M, Oger J. When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults? Mult Scler Int. 2011;2011:72487110.1155/2011/724871.
40. Koch M, Mostert J, Heersema D, De Keyser J. Progression in multiple sclerosis: further evidence of an age dependent process. J Neurol Sci. 2007;255(1-2): 35-41.
41. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006;129(pt 3):595-605.
42. Tremlett H, Yinshan Zhao, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008;14(3):314-324.
43. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study, I: clinical course and disability. Brain. 1989; 112(pt 1):133-146.
44. DeLuca GC, Ramagopalan SV, Herrera BM, et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A. 2007;104(52):20896- 20901.